Project Grant R01HL172363
Award Date
8/1/24
Completion Date
7/31/29
Dollars Obligated
$827K
Federal Agency
National Heart Lung and Blood Institute
Federal Grant Program
93.837
Assistance Type
Project Grant
Place of Performance
New York, NY 10029, USA
Similar Awards
This federal Project Grant award of $751,954 from the National Heart Lung and Blood Institute (NHLBI) under the Cardiovascular Diseases Research program (CFDA 93.837) will support research into investigating CXCR3 blockade as a potential precision therapy for cardiac sarcoidosis. The principal investigator will utilize single-cell multi-omics and T-cell receptor sequencing to define the key pathogenic T-cell subsets and interactions between adaptive and innate immunity that drive cardiac...
This Project Grant award of $252,854 from the National Heart, Lung, and Blood Institute (NHLBI) under the Cardiovascular Diseases Research federal grant program (CFDA 93.837) supports research to develop computational tools that can link single-cell RNA sequencing (scRNAseq) data to experimentally-testable predictions about the functional consequences of different cardiomyocyte subtypes. The project combines scRNAseq, mechanistic mathematical modeling, and physiological assays to investigate how...
This Project Grant award of $843,607.00 from the National Heart, Lung, and Blood Institute (NHLBI), under the Cardiovascular Diseases Research Federal Grant Program (CFDA 93.837), will support research at the Icahn School of Medicine at Mount Sinai to investigate the neuroimmune pathways that regulate sleep after myocardial infarction (MI) and the resulting brain-heart interactions that promote cardiac recovery. The research aims to document how thalamic neuroinflammation after MI leads to the...
This Project Grant award of $249,000 from the National Heart Lung and Blood Institute (CFDA 93.837 Cardiovascular Diseases Research) supports research to identify common and distinct metabolic and proteomic pathways associated with inflammation and fibrosis in pulmonary sarcoidosis. The research aims to use plasma samples from two studies to perform metabolomic and proteomic profiling, with the goal of defining molecular endotypes among pulmonary sarcoidosis patients and establishing a framework...
This Project Grant award, valued at $167,588 and commencing on March 1, 2025, was provided by the National Heart, Lung, and Blood Institute (NHLBI) under the Cardiovascular Diseases Research (CFDA 93.837) federal grant program. The award supports the research of Dr. Son Duong, a clinician-scientist at the Icahn School of Medicine at Mount Sinai (ISMMS), to develop and validate a prediction tool for assessing right ventricular size, function, and clinical outcomes in patients with repaired...
This $760,374 Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI) under the Cardiovascular Diseases Research program (CFDA 93.837) supports an integrative metabolomics study to identify diagnostic and prognostic blood signatures for pulmonary sarcoidosis. The study aims to incorporate single nucleotide polymorphisms (SNPs), gene expression, and plasma metabolomics/lipidomics to construct and validate predictive models for sarcoidosis diagnosis and progression....
This $1,526,628 Project Grant awarded by the National Heart Lung and Blood Institute (NHLBI), under the Cardiovascular Diseases Research program (CFDA 93.837), supports research to develop artificial intelligence (AI) methods to predict biological cardiovascular age from echocardiography imaging data. The key objectives are to: (I) identify trajectories of accelerated versus delayed cardiovascular aging, (II) discern contributors to accelerated cardiovascular aging phenotypes, and (III)...
This is a Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI), part of the National Institutes of Health (NIH), under the Cardiovascular Diseases Research (CFDA 93.837) program. The $827,682 award will fund a comprehensive research project to develop advanced imaging techniques, including dynamic contrast-enhanced CT, dual-energy CT, and electrical impedance tomography, to characterize pulmonary perfusion and guide personalized treatment of acute respiratory distress...
This $785,198 federal Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI) under the Cardiovascular Diseases Research program (CFDA 93.837) supports research at Albert Einstein College of Medicine to investigate the role of chaperone-mediated autophagy (CMA) in cardiac fibrosis and repair following myocardial infarction. The research aims to study how CMA, a process that selectively degrades specific proteins, regulates the phenotypic transitions and functions of...
This federal Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI) under the Cardiovascular Diseases Research program (CFDA 93.837) provides $126,750.00 to the Icahn School of Medicine at Mount Sinai to validate a novel clinical endpoint for graft-versus-host disease (GVHD) clinical trials. The project aims to demonstrate that a day 14 MAGIC (Mount Sinai Acute GVHD International Consortium) clinical response model and integrated response metric are more accurate...